PhoreMost has published new data validating its GlueSEEKER platform, a high-throughput technology designed to accelerate ...

Enter The 2025 PharmaTimes Clinical Researcher of the Year – The Americas! Introducing the Clinical Research Associate (CRA) ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

ACD440 is a topical gel formulation targeting peripheral neuropathic pain. The substance, a TRPV1 antagonist, shows powerful ...

One Biosciences has secured €15 million in Series A financing to expand its AI-powered single-cell transcriptomic platform, ...

Seaport Therapeutics has dosed the first patient in its phase 2b BUOY-1 trial of GlyphAllo, a novel oral prodrug of ...

North East and North Cumbria NHS has begun a year-long rollout of the Healthinote digital health platform to support patients ...

The MHRA has approved sebetralstat (Ekterly) as the first oral, on-demand treatment for hereditary angioedema (HAE) attacks ...

Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...

Researchers at Imperial College London have discovered that an unusual DNA structure could be key to reversing chemotherapy ...

Pierre Fabre Laboratories have received marketing authorisation in China for BRAFTOVI (encorafenib) in combination with ...